Search bioRxiv⌕ Search

Biology subjects

Slezak, T.

Publications and source records attributed to Slezak, T..

5 recordsLinked to original sources

Dynamic translocation of Inside-Out proteins to the cell surface underlies cellular adaptation to cancer-induced stress

Inside-out (I-O) protein display, the non-canonical surface localization of intracellular proteins, represents an underexplored feature of tumor cell biology. Here, we map the molecular landscape and trafficking mechanisms that control the presentation of I-O proteins on cancer cell membranes. Employing APEX2-mediated proximity biotinylation and a custom antibody generation and validation platform, we identified approximately 140 high-confidence I-O proteins, primarily ribosomal, proteasomal, chaperone, and translation factors, notably enriched in protein families associated with stress-response pathways. Validation of 500 antibodies encompassing 40 I-O targets across seven tumor cell lines confirmed selective and robust surface localization, while in vivo imaging in mouse xenografts demonstrated pronounced and tumor-specific antibody accumulation. I-O proteins were absent on PBMCs and in normal tissues, indicating cancer cell selectivity. Functional analyses revealed that I-O protein tethering to the membrane is dependent on heparan sulfate interactions; enzymatic removal of these glycans led to the clearance of I-O proteins from the cell surface. Notably, the removed proteins returned to baseline levels within six hours, indicating a dynamic balance related to ER-Golgi trafficking and cellular stress. Nearly half of these I-O proteins overlapped with known stress granule components; however, stress elements that promote stress granule formation do not similarly affect surface display of I-O proteins. Furthermore, I-O proteins are present on standard cancer cell lines under lower stress levels needed to induce stress granule formation, suggesting parallel yet mechanistically distinct aspects of the stress response. These findings position I-O display as a new paradigm in protein trafficking, different from traditional secretion pathways and closely linked to stress response.

biochemistry↗

A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy

Chimeric antigen receptor T (CAR-T) cell therapy has shown extraordinary results in treating hematological cancer. However, many patients relapse because of heterogeneous antigen expression and outgrowth of antigen lost variants. Other problems include on-target-off-tumor toxicity and the requirement for manufacturing of complex cellular products. Universal and modular CAR constructs offer significantly improved flexibility, safety and cost-effectiveness over conventional CAR constructs. Here we present a new chimeric-antigen receptor (CAR)-fragment antibody binder (Fab) platform based on an engineered protein G variant (GA1) and Fab scaffolds that present exquisite specificity and selectivity on antibody capture. The expression of GA1CAR on human CD8+T cells leads to antigen recognition and T cell effector function that can be modulated according to the affinity of the CAR for the Fab scaffold and of the Fab for the target. GA1CAR-T cells can recognize multiple Fab-antigen pairs on breast and ovarian cancer cell lines. Adoptive transfer of GA1CAR-T cells/Fabs in breast cancer xenograft models leads to effective tumor control. Rapid re-direction of the CAR-T cells to a new target can be achieved by using different Fabs. GA1CAR expression confers favorable phenotypic properties to T cells including a higher effector function upon exposure to antigen as compared to conventional scFv CAR-T cells. This highly versatile "plug and play" CAR-T platform has potential for application in personalized therapy, preventing antigen loss variant escape, decreasing toxicity and increasing access.

bioengineering↗

Molecular characterization of the archaic HLA-B*73:01 allele reveals presentation of a unique peptidome and skewed engagement by KIR2DL2

HLA class I alleles of archaic origin may have been retained in modern humans because they provide immunity against diseases to which archaic humans had evolved resistance. According to this model, archaic introgressed alleles were somehow distinct from those that evolved in African populations. Here we show that HLA-B*73:01, a rare allotype with putative archaic origins, has a relatively rare peptide binding motif with an unusually long-tailed peptide length distribution. We also find that HLA-B*73:01 combines a restricted and unique peptidome with high-cell surface expression, characteristics that make it well-suited to combat one or a number of closely-related pathogens. Furthermore, a crystal structure of HLA-B*73:01 in complex with KIR2DL2 highlights differences from previously solved structures with HLA-C molecules. These molecular characteristics distinguish HLA-B*73:01 from other HLA class I alleles previously investigated and may have provided early modern human migrants that inherited this allele with a selective advantage as they colonized Europe and Asia.

biochemistry↗

Engineered Protein-G variants for plug-and-play applications

We have developed a portfolio of antibody-based modules that can be prefabricated as standalone units and snapped together in plug-and-play fashion to create uniquely powerful multifunctional assemblies. The basic building blocks are derived from multiple pairs of native and modified Fab scaffolds and protein G (PG) variants engineered by phage display to introduce high pair-wise specificity. The variety of possible Fab-PG pairings provides a highly orthogonal system that can be exploited to perform challenging cell biology operations in a straightforward manner. The simplest manifestation allows multiplexed antigen detection using PG variants fused to fluorescently labeled SNAP-tags. Moreover, Fabs can be readily attached to a PG-Fc dimer module which acts as the core unit to produce plug-and-play IgG-like assemblies, and the utility can be further expanded to produce bispecific analogs using the "knobs into holes" strategy. These core PG-Fc dimer modules can be made and stored in bulk to produce off-the-shelf customized IgG entities in minutes, not days or weeks by just adding a Fab with the desired antigen specificity. In another application, the bispecific modalities form the building block for fabricating potent Bispecific T-cell Engagers (BiTEs), demonstrating their efficacy in cancer cell-killing assays. Additionally, the system can be adapted to include commercial antibodies as building blocks, greatly increasing the target space. Crystal structure analysis reveals that a few strategically positioned interactions engender the specificity between the Fab-PG variant pairs, requiring minimal changes to match the scaffolds for different possible combinations. This plug-and-play platform offers a user-friendly and versatile approach to enhance the functionality of antibody-based reagents in cell biology research.

bioengineering↗

FDA-ARGOS: A Public Quality-Controlled Genome Database Resource for Infectious Disease Sequencing Diagnostics and Regulatory Science Research

Infectious disease next generation sequencing (ID-NGS) diagnostics are on the cusp of revolutionizing the clinical market. To facilitate this transition, FDA proactively invested in tools to support innovation of emerging technologies. FDA and collaborators established a publicly available database, FDA dAtabase for Regulatory-Grade micrObial Sequences (FDA-ARGOS), as a tool to fill reference database gaps with quality-controlled genomes. This manuscript discusses quality control metrics for the proposed FDA-ARGOS genomic resource and outlines the need for quality-controlled genome gap filling in the public domain. Here, we also present three case studies showcasing potential applications for FDA-ARGOS in infectious disease diagnostics, specifically: assay design, reference database and in silico sequence comparison in combination with representative microbial organism wet lab testing; a novel composite validation strategy for ID-NGS diagnostics. The use of FDA-ARGOS as an in silico comparator tool could reduce the burden for completing ID-NGS clinical trials. In addition, use cases identifying Enterococcus avium and Ebola virus (Zaire ebolavirus variant Makona) demonstrate the utility of FDA-ARGOS as a reference database for independent performance validation of new tests and for documenting how one would use this database as an in silico sequence target comparator tool for ID-NGS validation, respectively.

microbiology↗